Q2 2019 13F Holders as of 30 Jun 2019
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share (the "Common Stock")
-
Shares outstanding
-
62.7M
-
Number of holders
-
265
-
Total 13F shares, excl. options
-
58.1M
-
Shares change
-
+5.31M
-
Total reported value, excl. options
-
$10.6B
-
Value change
-
+$990M
-
Put/Call ratio
-
1.58
-
Number of buys
-
139
-
Number of sells
-
-112
-
Price
-
$183.09
Significant Holders of Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) as of Q2 2019
321 filings reported holding SAGE - Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") as of Q2 2019.
Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) has 265 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 58.1M shares
of 62.7M outstanding shares and own 92.72% of the company stock.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (7.9M shares), FMR LLC (7.67M shares), VANGUARD GROUP INC (4.61M shares), Capital International Investors (3.14M shares), JENNISON ASSOCIATES LLC (2.95M shares), BlackRock Inc. (2.75M shares), WELLINGTON MANAGEMENT GROUP LLP (2.19M shares), Invesco Ltd. (2.02M shares), JANUS HENDERSON GROUP PLC (1.87M shares), and Bellevue Group AG (1.32M shares).
This table shows the top 265 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.